Halford Jason C G
University of Liverpool, Kissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, Eleanor Rathbone Building, Bedford Street South, Liverpool, UK.
Curr Opin Investig Drugs. 2006 Apr;7(4):312-8.
A number of anti-obesity drugs are currently undergoing clinical development. These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety signals, such as glucagon-like peptide-1 (exenatide, exenatide-LAR and liraglutide), peptide YY (intranasal PYY3-36 and AC-162325) and amylin (pramlintide); (iii) drugs that block fat absorption, such as the novel lipase inhibitors cetilistat and GT-389255; and (iv) a human growth hormone fragment (AOD-9604) that increases adipose tissue breakdown. Of these, only rimonabant has got as far as completing phase III clinical trials. This review will provide an overview of the most prominent drugs currently undergoing clinical development as potential anti-obesity therapies.
目前有多种抗肥胖药物正在进行临床开发。这些药物包括：（i）中枢作用药物，如去甲肾上腺素能和多巴胺能再摄取抑制剂瑞伐法辛、内源性大麻素拮抗剂利莫那班、选择性5-羟色胺5-HT2c激动剂APD-356以及油酰雌酮；（ii）针对外周阶段性饱腹感信号的药物，如胰高血糖素样肽-1（艾塞那肽、长效艾塞那肽和利拉鲁肽）、肽YY（鼻内给予的PYY3-36和AC-162325）以及胰淀素（普兰林肽）；（iii）阻断脂肪吸收的药物，如新型脂肪酶抑制剂西替利司他和GT-389255；以及（iv）一种可增加脂肪组织分解的人生长激素片段（AOD-9604）。其中，只有利莫那班已进入III期临床试验阶段。本综述将概述目前作为潜在抗肥胖疗法正在进行临床开发的最主要药物。
